SCHEMBL5375984

SCHEMBL5375984

CNC1CCN(C2CCN(C(C)C)CC2)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.37
PARP2 Q9UGN5 2/20 0.37
FPR2 P25090 4/20 0.32
HRH3 Q9Y5N1 3/20 0.32
ALDH1A1 P00352 1/20 0.32
JAK2 O60674 1/20 0.31
TIPARP Q7Z3E1 1/20 0.31
PRKCG P05129 1/20 0.30
PRKCB P05771 1/20 0.30
PRKCA P17252 1/20 0.30
PRKCH P24723 1/20 0.30
PRKCE Q02156 1/20 0.30
PRKCZ Q05513 1/20 0.30
PRKCD Q05655 1/20 0.30
CAMK2B Q13554 1/20 0.30
CAMK2G Q13555 1/20 0.30
CAMK2D Q13557 1/20 0.30
CAMK2A Q9UQM7 1/20 0.30
KCNH2 Q12809 1/20 0.30
PDE4B Q07343 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13674419 0.80 HSD11B1 (0.43) FPR2HRH3ALDH1A1
Hydrochloric Acid SCHEMBL4525101 0.78 HSD11B1 (0.42) FPR2HRH3ALDH1A1
SCHEMBL20315443 0.77 PARP1 (0.41) PARP1PARP2HRH3ALDH1A1PRKCG
SCHEMBL14968926 0.77 FPR2 (0.50) PARP1FPR2
SCHEMBL4626256 0.77 DPP4 (0.42) PARP1PARP2HRH3ALDH1A1JAK2
SCHEMBL14169980 0.73 ALDH1A1 (0.40) HRH3ALDH1A1
SCHEMBL14178991 0.73 NOS3 (0.37) ALDH1A1
SCHEMBL14170131 0.73 ALDH1A1 (0.40) HRH3ALDH1A1
SCHEMBL16011008 0.72 DPP4 (0.39) FPR2HRH3TIPARP
SCHEMBL16011007 0.72 DPP4 (0.39) FPR2HRH3TIPARP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312218-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB CO. (US) 2007-12-25 US claimed
US-20070099922-A1 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS HAN WEI 2007-05-03 US claimed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US claimed
US-7312218-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB CO. (US) 2007-12-25 US disclosed
US-20070099922-A1 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS HAN WEI 2007-05-03 US disclosed
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 US disclosed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099922-A1 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS TFPI, F12, F5 PARP1 1406/4885PARP2 3321/4885FPR2 3990/4885
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors TFPI, F12, F5 PARP1 1406/4885PARP2 3321/4885FPR2 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.